Women’s Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) – Global forecast to 2024

2020-01-17
Price :
Published : Jan-2020
No. of Pages : 146

“Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.”

The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth.

“Prolia is the largest and fastest-growing segment of the market.”

On the basis of drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28).Prolia is the largest and fastest-growing segment of the market. The increasing unit demand for prolia due to the high prevalence of postmenopausal osteoporosis among women in the US is one of the major factors responsible for the large share and high growth rate of this drug.

“The postmenopausal osteoporosis segment accounted for the largest share in 2019.”

Based on application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market in 2018.The growing prevalence of postmenopausal osteoporosis and the focus of pharmaceutical players on providing effective drugs for the treatment of post menopausal osteoporosis are some of the key factors supporting the growth of this segment. This segment is also expected to register the highest CAGR during the forecast period.

“North America to be the largest and the fastest-growing regional market.”

North America, which comprises the US and Canada, forms the largest market for women’s healthcare. Growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending are some of the major factors responsible for the large share and high growth of this market. Additionally, the increasing median age of first-time pregnancies and the growing prevalence of PCOS& postmenopausal osteoporosis also propels the market growth in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
  • By Designation: C-level (33%), D-level (29%), and Others (38%)
  • By Region: North America (58%), Europe (19%), Asia (14%), and the RoW (9%)

List of Companies Profiled in the Report

  • Bayer AG (Germany)
  • Allergan (Dublin)
  • Merck & Co. (US)
  • Pfizer Inc. (US)
  • Amgen (US)
  • Agile Therapeutics Inc. (US)
  • Ferring Pharmaceuticals (US)
  • Mylan N.V. (US)
  • Lupin (India)
  • Blairex Laboratories (US)
  • Apothecus Pharmaceutical (US)
  • Eli Lilly And Company (US)
  • Novartis AG (Switzerland)
  • Johnson & Johnson(US)

Research Coverage:

This report provides a study of the women’s healthcare market. It aims at estimating the size and future growth potential of the market across different segments, such as drug, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall women’s healthcare market and its sub segments. This report will also help stakeholders understand the competitive landscape, and gain insights to position their business better and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

Filed in: Pharmaceutical
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Telehealth Market by Component Software & Services (RPM, RTM), Application (Teleradiology, telestroke, teleICU), Hardware (Glucose Meters), End-User (Provider, Payer, Patient), Delivery Mode (On-Premise, Cloud) Trends & Global Forecast to 2025

“The telehealth market is projected to grow at a CAGR of 16.9% during the forecast period (2020–2025).” The global telehealth market is projected to reach USD 55.6 billion by 2025 from USD 25.5 billion in 2020, at a CAGR of 16.9 % during the forecast period. The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, and government support and raising awareness. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. “The software & services segment will grow at the highest rate during the forecast period.” Base......
$4950

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

“The global biosimilars  market size is projected to register a CAGR of 24.7% during the forecast period.” The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market. “The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period.” The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept......
$5650

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020

Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2020" provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generate......
$2500

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020

Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports ......
$2500

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020

Schizoaffective Disorder Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Schizoaffective Disorder Global Clinical Trials Review, H1, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario. This report provides top line data relating to the clinical trials on Schizoaffective Disorder. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Post Operative Nausea And Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Post Operative Nausea And Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020

Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Seasonal Allergic Rhinitis Global Clinical Trials Review, H1, 2020" provides an overview of Seasonal Allergic Rhinitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Seasonal Allergic Rhinitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2020" provides an overview of Chemotherapy Induced Nausea and Vomiting Clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Nausea and Vomiting. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Cirrhosis Global Clinical Trials Review, H1, 2020

Cirrhosis Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Cirrhosis Global Clinical Trials Review, H1, 2020" provides an overview of Cirrhosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy